ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0334

Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus

Sarah Lieber1, Yvonne Shea2, Deanna Jannat-Khah2, John Carrino2, M. Carrington Reid3 and Lisa Mandl1, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Weill Cornell Medicine, New York, NY

Meeting: ACR Convergence 2023

Keywords: body composition, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarcopenia, i.e., loss of skeletal muscle mass and strength, has been associated with multiple adverse health outcomes, including mortality. Although limited data suggest that sarcopenia is more prevalent among adults with systemic lupus erythematosus (SLE) across the lifespan relative to comparators, current methods for sarcopenia assessment (e.g., body composition-specific dual energy x-ray absorptiometry) are not widely available. Therefore, we assessed associations of a simple self-report screening tool for sarcopenia (SARC-F) with functional status outcomes in adults with SLE [1].

Methods: We recruited women ≥18 years with validated SLE followed at our hospital. Sociodemographic and SLE disease characteristics, as well as observed and self-report functional status measures (hand grip strength, 4-meter (m) walk test, self-report FRAIL scale, Valued Life Activities self-report disability) were obtained. Participants completed the SARC-F, which includes questions related to strength, assistance walking, rising from a chair, climbing stairs, and falls. Sociodemographic features, SLE disease characteristics, and functional status measures were compared using descriptive statistics between participant groups, with SARC-F scores dichotomized as ≥4 versus < 4 based on established cut points. Pearson correlations and linear and logistic regression were used to evaluate the relationship between the SARC-F as a continuous and dichotomous score with functional status measures, including after adjustment for confounders (i.e., age, race, ethnicity, disease activity, and organ damage).

Results: Of 47 participants, 16 (34%) had SARC-F score ≥4. Participants with SARC-F ≥4 had greater organ damage and worse functional status measures than those with SARC-F < 4 (all p< 0.01). SARC-F continuous scores were significantly correlated with hand grip strength, 4-m walk test, and self-report disability (all p< 0.01) and significantly correlated with all functional status measures (p< 0.01 to p=0.046). Dichotomous SARC-F was significantly associated with 4-m walk test (p< 0.01), including after adjustment for confounders, and there was a trend toward significance with hand grip strength and self-report disability (both p=0.06).

Conclusion: In this exploratory study of adult women with SLE, SARC-F was significantly associated with multiple functional status measures, suggesting that the SARC-F may be a valid point-of-care screening tool for sarcopenia in women with SLE.

Reference: 1. Malmstrom et al. J Cachexia Sarcopenia Muscle 2016;7:28-36.

Supporting image 1

Table 1

Supporting image 2

Table 2

Supporting image 3

Table 3


Disclosures: S. Lieber: None; Y. Shea: None; D. Jannat-Khah: AstraZeneca, 12, stock ownership, Cytodyn, 12, stock ownershil[, Walgreens Boots Alliance, 12, stock ownership; J. Carrino: American College of Rheumatology, 12, Editorial Board Member, AstraZeneca, 2, Covera Health, 2, Eli Lilly & Company, 2, Globus Medical, Inc., 2, International Society of Osteoarthritis Imaging, 12, Editorial Board Member, Pfizer, 2, Radiology Society of North America, 12, Editorial Board Member, Regeneron Phamaceuticals, Inc., 2; M. Reid: None; L. Mandl: Annals of Internal Medicine, 12, Associate Editor, Regeneron Pharmaceuticals, 5, Up-to-Date, 9.

To cite this abstract in AMA style:

Lieber S, Shea Y, Jannat-Khah D, Carrino J, Reid M, Mandl L. Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/association-of-a-self-report-screening-tool-for-sarcopenia-sarc-f-with-functional-status-outcomes-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-a-self-report-screening-tool-for-sarcopenia-sarc-f-with-functional-status-outcomes-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology